GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Natera Inc (NAS:NTRA) » Definitions » Cyclically Adjusted PB Ratio

Natera (Natera) Cyclically Adjusted PB Ratio : 31.84 (As of May. 16, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Natera Cyclically Adjusted PB Ratio?

As of today (2024-05-16), Natera's current share price is $107.31. Natera's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $3.37. Natera's Cyclically Adjusted PB Ratio for today is 31.84.

The historical rank and industry rank for Natera's Cyclically Adjusted PB Ratio or its related term are showing as below:

NTRA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 12.97   Med: 20.65   Max: 31.32
Current: 31.32

During the past years, Natera's highest Cyclically Adjusted PB Ratio was 31.32. The lowest was 12.97. And the median was 20.65.

NTRA's Cyclically Adjusted PB Ratio is ranked worse than
98.5% of 133 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.95 vs NTRA: 31.32

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Natera's adjusted book value per share data for the three months ended in Mar. 2024 was $6.497. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.37 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Natera Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Natera's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Natera Cyclically Adjusted PB Ratio Chart

Natera Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 19.07

Natera Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 14.98 19.07 27.15

Competitive Comparison of Natera's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Natera's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Natera's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Natera's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Natera's Cyclically Adjusted PB Ratio falls into.



Natera Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Natera's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=107.31/3.37
=31.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Natera's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Natera's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=6.497/129.4194*129.4194
=6.497

Current CPI (Mar. 2024) = 129.4194.

Natera Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -3.835 99.070 -5.010
201503 1.354 99.621 1.759
201506 -4.427 100.684 -5.690
201509 4.125 100.392 5.318
201512 3.670 99.792 4.760
201603 3.558 100.470 4.583
201606 3.164 101.688 4.027
201609 2.679 101.861 3.404
201612 2.022 101.863 2.569
201703 1.395 102.862 1.755
201706 0.957 103.349 1.198
201709 0.562 104.136 0.698
201712 0.470 104.011 0.585
201803 -0.071 105.290 -0.087
201806 -0.397 106.317 -0.483
201809 0.917 106.507 1.114
201812 0.518 105.998 0.632
201903 0.079 107.251 0.095
201906 1.329 108.070 1.592
201909 1.195 108.329 1.428
201912 3.573 108.420 4.265
202003 3.292 108.902 3.912
202006 3.817 108.767 4.542
202009 6.285 109.815 7.407
202012 5.639 109.897 6.641
202103 4.260 111.754 4.933
202106 3.380 114.631 3.816
202109 8.029 115.734 8.978
202112 6.867 117.630 7.555
202203 5.634 121.301 6.011
202206 4.588 125.017 4.750
202209 3.717 125.227 3.841
202212 6.343 125.222 6.556
202303 5.739 127.348 5.832
202306 5.227 128.729 5.255
202309 6.594 129.860 6.572
202312 6.400 129.419 6.400
202403 6.497 129.419 6.497

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Natera  (NAS:NTRA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Natera Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Natera's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Natera (Natera) Business Description

Traded in Other Exchanges
N/A
Address
13011 McCallen Pass, Building A Suite 100, Austin, TX, USA, 78753
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Executives
Michael Burkes Brophy officer: Chief Financial Officer 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Steven Leonard Chapman officer: Chief Operating Officer 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Daniel Rabinowitz officer: CHIEF LEGAL OFFICER C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN TX 78753
Jonathan Sheena director, officer: Chief Technology Officer C/O NATERA, INC., 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Gail Boxer Marcus director 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Rowan E Chapman director 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Matthew Rabinowitz director, officer: Chief Executive Officer C/O NATERA, INC., 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Brinkley Ruth Williams director C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Robert Alan Schueren officer: Chief Operating Officer 7400 PASEO PADRE PARKWAY, FREMONT CA 94555
Roelof Botha director C/O SEQUOIA CAPITAL, 2800 SAND HILL RD, SUITE 101, MENLO PARK CA 94025
Herm Rosenman officer: Chief Financial Officer OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
Todd C Cozzens director ONE FEDERAL STREET, 25TH FLOOR, BOSTON MA 02110
Monica Bertagnolli director C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Roy D. Baynes director C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130